1. Introduction: What Is the Difference Between XEOMIN and BOTOX?

XEOMIN and BOTOX are distinct botulinum toxin type A (BoNT-A) products used in aesthetic and therapeutic medicine.

XEOMIN contains incobotulinumtoxinA and is manufactured by Merz. BOTOX contains onabotulinumtoxinA and is manufactured by Allergan, an AbbVie company. Although both products act by temporarily reducing acetylcholine release at cholinergic nerve terminals, they differ in their formulations, manufacturing processes and product-specific potency assays. ［1,2］

A central formulation distinction is that XEOMIN contains botulinum neurotoxin type A without the associated complexing proteins found in certain other botulinum toxin preparations. BOTOX is formulated using a botulinum toxin type A neurotoxin complex.

These differences are relevant to understanding product composition, but they do not independently establish a difference in clinical efficacy, duration or safety.

Importantly, XEOMIN and BOTOX have been compared directly in randomized clinical trials for glabellar frown lines. Published studies include equivalence and non-inferiority designs, as well as a trial investigating different numerical doses. ［3–5］

The findings are best understood by examining the exact product, dose, population, endpoint and statistical framework used in each study.

2. Product Background: IncobotulinumtoxinA vs OnabotulinumtoxinA

XEOMIN and BOTOX belong to the same therapeutic class but have different nonproprietary names.

Table 1. XEOMIN and BOTOX Product Overview

Feature

XEOMIN

BOTOX

Nonproprietary name

IncobotulinumtoxinA

OnabotulinumtoxinA

Manufacturer

Merz

Allergan / AbbVie

Drug class

Botulinum toxin type A

Botulinum toxin type A

Formulation characteristic

Neurotoxin without associated complexing proteins

Neurotoxin complex

Potency units

Product-specific

Product-specific

Clinical evidence

Randomized trials in aesthetic and therapeutic indications

Randomized trials in aesthetic and therapeutic indications

Product labeling should be consulted for the exact formulation, excipients, approved indications and administration instructions applicable to the intended market. ［1,2］

3. Formulation: What Does “Free From Complexing Proteins” Mean?

Botulinum toxin type A preparations may differ in the protein components present in the final pharmaceutical product.

The active neurotoxin is responsible for the intended pharmacological effect. Associated proteins, sometimes called complexing or accessory proteins, may be present in certain preparations.

XEOMIN is formulated without these associated complexing proteins. Its active ingredient is incobotulinumtoxinA.

BOTOX contains onabotulinumtoxinA in a neurotoxin-complex formulation.

3.1 Does the Formulation Difference Affect Clinical Outcomes?

A formulation difference is a documented product characteristic. It should not be used on its own to predict an individual patient's clinical response.

Questions about efficacy, onset, duration, diffusion, adverse events and immunogenicity require appropriate clinical evidence.

For example, the absence of complexing proteins should not automatically be translated into a claim that XEOMIN has a longer duration of action or produces fewer adverse events than BOTOX.

Similarly, the presence of a neurotoxin complex does not independently establish greater clinical potency.

Comparative clinical trials provide more relevant evidence for evaluating outcomes in a defined population.

3.2 What About Immunogenicity?

Immunogenicity refers to the potential for a biological product to induce an immune response, including the formation of antibodies.

Neutralizing antibodies may be relevant when evaluating reduced clinical response after repeated botulinum toxin treatment.

However, immunogenicity is influenced by multiple factors, including the formulation, administered dose, treatment frequency, indication and patient characteristics.

A formulation description alone cannot establish comparative rates of neutralizing-antibody formation. Such claims require appropriate product-specific evidence.

4. Why XEOMIN and BOTOX Potency Units Must Be Interpreted Separately

Botulinum toxin potency is expressed in units, but those units are defined by the relevant product's biological assay.

The BOTOX Cosmetic prescribing information states that its potency units are specific to its preparation and assay method and are not directly comparable to, or convertible into, units of other botulinum toxin products. ［2］

Accordingly, numerical doses used in a clinical trial should be interpreted as part of that trial's protocol.

Table 2. How to Interpret Cross-Product Units

Observation

Appropriate Interpretation

A trial uses 20 U of each product

The study tested those doses in its defined population

A trial reports equivalence

The finding applies to the prespecified endpoint and equivalence margins

A trial reports non-inferiority

The finding applies to its prespecified non-inferiority margin

Different numerical doses are compared

The ratio describes the study protocol, not a universal conversion rule

Both products contain BoNT-A

Their labeled potency units remain product-specific

Even when equal numerical doses are investigated, the result does not establish that all doses, indications or treatment patterns are interchangeable.

5. Direct Comparative Evidence: XEOMIN vs BOTOX in Glabellar Lines

Glabellar lines are the vertical frown lines that appear between the eyebrows, particularly during contraction of the corrugator and procerus muscles.

Several randomized studies have compared incobotulinumtoxinA with onabotulinumtoxinA for this indication.

The studies use different statistical approaches, including equivalence and non-inferiority. These approaches should be distinguished when interpreting their conclusions. ［3–5］

6. The 2015 Randomized Equivalence Trial

Kane MAC and colleagues published a randomized, double-blind trial investigating the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. ［3］

The study evaluated the products using a predefined equivalence framework.

6.1 What Is an Equivalence Trial?

An equivalence trial is designed to determine whether the difference between two treatments falls within a prespecified range in both directions.

This differs from a non-inferiority trial, which is designed to exclude an unacceptable loss of efficacy relative to the comparator.

Table 3. Equivalence vs Non-Inferiority

Study Design

Primary Question

Equivalence

Is the treatment difference contained within predefined upper and lower margins?

Non-inferiority

Is the investigated treatment not worse than the comparator by more than a predefined margin?

Superiority

Is one treatment statistically superior to the comparator for the specified endpoint?

The 2015 trial provides direct comparative evidence within its defined glabellar-line protocol.

Its equivalence findings should not be generalized into a statement that XEOMIN and BOTOX are identical in formulation, potency units or all clinical effects.

7. The 2010 Non-Inferiority Trial

Sattler G and colleagues published a randomized comparative study evaluating the non-inferiority of incobotulinumtoxinA relative to onabotulinumtoxinA in glabellar frown lines. ［4］

The study used a prespecified non-inferiority framework to evaluate the clinical response.

7.1 What Does This Trial Add?

The study provides direct active-comparator evidence for incobotulinumtoxinA in the investigated aesthetic indication.

Together with the equivalence trial, it shows that the XEOMIN–BOTOX comparison has been evaluated through more than one randomized clinical protocol.

However, the statistical conclusions remain specific to the endpoints, margins and treatment conditions used by the investigators.

7.2 Why Study Design Matters

A successful non-inferiority result is not equivalent to a finding of superiority.

It also does not mean that the products have identical onset, duration, diffusion characteristics or adverse-event profiles.

Those outcomes require their own measurements and analyses.

8. A Trial Comparing 20 U of BOTOX With 30 U of XEOMIN

A separate randomized, double-blind study published in the Journal of Cosmetic and Laser Therapy compared 20 U of onabotulinumtoxinA with 30 U of incobotulinumtoxinA for glabellar lines. ［5］

This trial illustrates why the numerical doses in published studies must be reported accurately.

Table 4. Investigated Doses

Product

Dose Used in the Study

OnabotulinumtoxinA

20 U

IncobotulinumtoxinA

30 U

The 20-U versus 30-U comparison is a feature of this specific study protocol.

It should not be interpreted as establishing a general 2:3 conversion ratio between BOTOX and XEOMIN.

The clinical findings must be evaluated using the study's actual endpoints, assessment schedule and statistical analysis.

9. What Do the Comparative Trials Establish?

The identified studies demonstrate that XEOMIN and BOTOX have been evaluated in direct randomized comparisons for glabellar lines.

They also illustrate that different trial designs may address different clinical questions.

Table 5. Overview of Direct Comparative Studies

Study

Comparison

Main Research Framework

Sattler et al., 2010

IncobotulinumtoxinA vs onabotulinumtoxinA

Non-inferiority

Kane et al., 2015

IncobotulinumtoxinA vs onabotulinumtoxinA

Equivalence

J Cosmet Laser Ther., 2012

30 U incobotulinumtoxinA vs 20 U onabotulinumtoxinA

Randomized, double-blind comparison

The original publications should be consulted for exact responder definitions, assessment time points, statistical margins and adverse-event results. ［3–5］

The evidence supports study-specific comparative conclusions rather than a universal statement that the products can be substituted without regard to indication or dosing.

10. Can the Trials Establish Which Product Lasts Longer?

Duration of effect is a separate clinical outcome from early treatment response.

A trial may report response at a particular visit, such as Week 4, but that finding does not by itself establish the total duration of treatment effect.

To compare duration, investigators must define an appropriate durability endpoint and collect follow-up data over the relevant period.

When reviewing a duration study, the following information is important:

• The exact products and doses investigated.

• The definition of onset and duration.

• The clinical indication and assessment method.

• The follow-up schedule.

• The statistical analysis and uncertainty around the reported findings.

A duration result from glabellar-line treatment should not automatically be extended to other aesthetic regions or therapeutic indications.

11. What About Comparative Safety?

XEOMIN and BOTOX have product-specific safety information, contraindications and warnings. ［1,2］

Comparative trials may provide information about adverse events observed under their study protocols, but the interpretation depends on sample size, follow-up duration and the events being measured.

A study designed primarily to assess efficacy may not have sufficient statistical power to detect small differences in uncommon adverse events.

Similarly, a finding of equivalent or non-inferior efficacy does not establish equivalent safety across every patient population.

Clinical use should follow the current locally approved prescribing information, including contraindications, precautions and administration requirements.

12. How Does Neuronox Compare With This Evidence?

Neuronox is another botulinum toxin type A product, manufactured by Medytox Inc. in the Republic of Korea.

It has its own randomized comparative evidence, including a Phase III study in glabellar lines and studies in selected therapeutic indications. ［6–9］

The glabellar-line trial included 314 participants and reported Week-4 responder rates of 93.7% for the Neuronox preparation and 94.5% for onabotulinumtoxinA. The study met its prespecified non-inferiority criterion. ［6］

Published research has also evaluated Neuronox or Meditoxin, as named in the respective publications, in essential blepharospasm, cerebral-palsy spastic equinus and post-stroke upper-limb spasticity. ［7–9］

Table 6. Distinguishing the Evidence Programs

Product

Direct Comparator in Selected Studies

Investigated Indications

XEOMIN

OnabotulinumtoxinA

Glabellar lines

BOTOX

IncobotulinumtoxinA and other treatments

Aesthetic and therapeutic indications

Neuronox

OnabotulinumtoxinA

Glabellar lines and selected therapeutic indications

These studies form separate product-specific evidence bases. Their findings should be interpreted according to the respective trial designs, populations and endpoints.

13. Frequently Asked Questions

Is XEOMIN the same product as BOTOX?

No. XEOMIN contains incobotulinumtoxinA, while BOTOX contains onabotulinumtoxinA. They are distinct products with different formulations and product-specific potency units.

Does XEOMIN contain complexing proteins?

XEOMIN is formulated without the associated complexing proteins found in certain other botulinum toxin preparations. ［1］

Has XEOMIN been compared directly with BOTOX?

Yes. Published randomized trials have compared incobotulinumtoxinA with onabotulinumtoxinA in glabellar frown lines. ［3–5］

Did the trials demonstrate equivalence?

A randomized, double-blind trial published by Kane and colleagues investigated equivalence using a prespecified statistical framework. ［3］

Is there non-inferiority evidence?

Yes. Sattler and colleagues published a comparative study evaluating non-inferiority of incobotulinumtoxinA relative to onabotulinumtoxinA in glabellar lines. ［4］

Are XEOMIN and BOTOX units interchangeable?

Potency units are product-specific. Numerical dose ratios used in clinical trials should not be treated as universal conversion rules.

Does the absence of complexing proteins establish lower immunogenicity?

The formulation characteristic alone is insufficient to establish a comparative clinical immunogenicity claim. Appropriate product-specific evidence is required.

Has Neuronox also been studied against BOTOX?

Yes. Randomized studies have compared Neuronox or Meditoxin with onabotulinumtoxinA in glabellar lines and selected therapeutic indications. ［6–9］

14. Conclusion

XEOMIN and BOTOX are distinct botulinum toxin type A products containing incobotulinumtoxinA and onabotulinumtoxinA, respectively.

A documented formulation distinction is that XEOMIN is manufactured without associated complexing proteins. However, formulation differences should be considered separately from clinical outcome claims.

Randomized studies have compared XEOMIN and BOTOX directly in glabellar lines, including equivalence and non-inferiority trials. Another study investigated 30 U of incobotulinumtoxinA against 20 U of onabotulinumtoxinA. These findings are specific to their respective protocols and do not establish a universal dose-conversion rule. ［3–5］

Neuronox also has a separate randomized clinical evidence program, including direct comparison with onabotulinumtoxinA in glabellar lines and selected therapeutic indications. ［6–9］

An evidence-based product comparison should therefore distinguish formulation, potency units, approved indications and study-specific clinical outcomes.

References

［1］ XEOMIN (incobotulinumtoxinA). Official product and safety information. Merz Aesthetics. Accessed September 2026.

［2］ BOTOX Cosmetic (onabotulinumtoxinA). Full Prescribing Information. AbbVie/Allergan Aesthetics. U.S. prescribing information; locally applicable version to be verified before publication.

［3］ Kane MAC, et al. A randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. Dermatol Surg. 2015;41:1310–1319. doi:10.1097/DSS.0000000000000531.

［4］ Sattler G, et al. Noninferiority of incobotulinumtoxinA compared with onabotulinumtoxinA in glabellar frown lines. Dermatol Surg. 2010;36 Suppl 4:2146–2154. doi:10.1111/j.1524-4725.2010.01706.x.

［5］ A randomised, double-blind comparison of 20 U onabotulinumtoxinA with 30 U incobotulinumtoxinA for glabellar lines. J Cosmet Laser Ther. 2012;14:296–303. doi:10.3109/14764172.2012.738913.

［6］ Lee WS, et al. Efficacy and safety of a new botulinum toxin type A for glabellar lines: randomized, double-blind, active-controlled, multicenter phase III study. Dermatol Surg. 2013;39:171–178. doi:10.1111/dsu.12072.

［7］ Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23:137–141. doi:10.3341/kjo.2009.23.3.137.

［8］ Kim K, Shin HI, Kwon BS, et al. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53:239–244. doi:10.1111/j.1469-8749.2010.03830.x.

［9］ Nam HS, et al. Efficacy and safety of Neuronox versus BOTOX for post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS ONE. 2015;10:e0128633. doi:10.1371/journal.pone.0128633.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.